Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nuvelo has presented encouraging preclinical data that demonstrated the mechanism of action and the potent therapeutic activity of NU206 in chemotherapy or radiation-induced oral mucositis models.
Subscribe to our email newsletter
The study, conducted in mouse models of oral mucositis, showed that NU206 (R-spondin1) regenerated basal layer epithelial cells and accelerated cell repair by stimulating the Wnt pathway, a signaling pathway that is critical for cell growth and differentiation during homeostasis and pathogenesis.
Ted Love, chairman and CEO of Nuvelo, said: “We are on track to begin a Phase I trial with NU206 in the second quarter of this year, and are also assessing the therapeutic potential of other secreted proteins in the R-spondin family through our Wnt therapeutics program, which targets a range of indications where cell regeneration and differentiation are important to disease processes, including gastrointestinal disease, bone disorders, wound healing and cancer.”